Thymosin Alpha-1 + Epitalon Stack: Safety, Monitoring, and Protocol

Is the stack safe?

Each peptide carries its own unknowns. Epitalon has no clinical safety evidence [2], while thymosin alpha-1 has trial data but no US approval [1]. FDA's review found three human studies of epitalon, and none of them involved thymosin alpha-1 [2]. The combination's safety is therefore unknown.

Thymosin alpha-1: what the safety record shows

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, described as an immune modulator that augments T-cell function [6][1]. It is not FDA-approved; FDA's December 2024 review notes four US orphan drug designations, which are a separate process from approval [1]. The agency lists national authorizations in Italy (adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults with compensated liver disease and virus replication) and Hong Kong [1]. The finished injectable sold in those markets is Zadaxin, 1.6 mg per vial, which is not interchangeable with bulk peptide powder [1].

A 2026 Cochrane review included 10 randomized trials involving 1,349 adults with chronic hepatitis B, published 1991 to 2018 [3]. Thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [3]. The same review found little to no effect on quality of life, rated the certainty of its key findings low to very low, and the reviewers said they were not sure it helps [3]. A 1991 placebo-controlled pilot in 12 people, seven of whom received thymosin fraction 5 or thymosin alpha-1, reported no significant side effects [7].

FDA's search of its adverse-event database in April 2024 returned zero reports for the peptide [1]. Reviews written by authors tied to the manufacturer describe more than 4,400 people enrolled in trials and more than 17 million doses given after marketing, with adverse experiences 'infrequent and mild' — treat that as company-linked data [1].

FDA's compounding page lists thymosin alpha-1 in the 'nominated but withdrawn' table, and its posted concerns remain: 'significant risk for immunogenicity for certain routes of administration,' peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [4].

Epitalon: what the safety record shows

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, designed from the amino-acid content of epithalamin, a pineal gland extract; FDA treats the two as different substances, so epithalamin studies are not epitalon studies [2]. It is not FDA-approved and is not a component of any approved product. FDA's July 2026 review found no USP or National Formulary monograph and no approved product in Canada, Australia, the UK or several European countries, and none authorized by the European Medicines Agency [2].

FDA found no clinical study that assessed epitalon's safety [2]. Its search of the adverse-event database through December 8, 2025 and of its food and supplement complaint system through December 5, 2025 retrieved no epitalon reports, and the agency concluded there are no clinical data supporting epitalon's safety [2]. For compounding, FDA's stated position is that it 'has not identified safety-related information regarding epitalon for the proposed route of administration,' and it raised immunogenicity risk from aggregation and impurities in injectable peptides [4].

The specific worry is mechanistic. In cultured human fetal fibroblasts that lack telomerase, epitalon induced telomerase activity and telomere elongation [8]. A 2025 cell study found dose-dependent telomere lengthening in normal epithelial and fibroblast cells through telomerase upregulation, and telomere extension in breast cancer cell lines through alternative lengthening of telomeres [9]. FDA warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic, and it called the mouse cancer and chromosome-damage studies too limited to show safety [2]. That concern is theoretical rather than a documented human harm.

What the human epitalon studies actually measured

FDA found three human studies of epitalon: two sublingual studies in night-shift workers and one eye injection study in retinitis pigmentosa [2]. In one sublingual study, 75 healthy women aged 40 to 50 were enrolled; 40 with low melatonin output were split into two groups of 20 and received a sublingual spray delivering about 0.5 mg per day, or placebo, for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo, and 83% versus 25% were described as improved in mood and physical condition — but no sleep outcomes were measured and blinding was not specified [2]. An older controlled study of epitalon injected beside the eye in retinitis pigmentosa reported a positive clinical effect in 90% of patients with degenerative retinal lesions, but the abstract gives no sample size or design detail to judge the result [10][2]. A 2026 narrative review concluded that epitalon is 'biologically active but clinically unproven' [11].

What dosing have these peptides actually been tested at?

Neither peptide has a US-approved dose [1][2]. The Italian Zadaxin label describes 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. Trial regimens differed — three times weekly for 24 weeks alongside lymphoblastoid interferon in a 98-person hepatitis B trial [12], and twice weekly for 6 months in the 12-person pilot [7].

For epitalon, there is no approved dose, and dose-ranging evidence is inadequate [2][11]. Websites FDA reviewed suggest 5 mg to 10 mg per day by subcutaneous injection or orally in cycles, with one site suggesting a course every 4 months; FDA treated those numbers as marketing, not evidence [2]. The routes actually studied in people were a sublingual spray delivering about 0.5 mg per day for 20 days and a parabulbar (beside the eye) injection for retinitis pigmentosa [2].

What monitoring does the evidence support?

No validated laboratory-monitoring schedule or laboratory thresholds for this combination appear in the available information. What exists are precautions. The Italian Zadaxin label lists pregnancy and breastfeeding as contraindications and advises caution in people with allergies or autoimmune disease and in those taking other immune-modulating drugs [1]. FDA's compounding review adds immunogenicity risk for certain injection routes and problems with peptide impurities and characterization [4]. For epitalon, FDA found no pharmacokinetic data [2].

Where the two peptides stand with FDA

Neither peptide is on FDA's list of bulk drug substances that can be used in pharmacy compounding. Thymosin alpha-1 appears in none of the three categories on FDA's interim-policy list for state-licensed pharmacies and physicians (updated May 14, 2026); on FDA's list for outsourcing facilities (updated March 21, 2025) it sits in category 3, 'nominated without adequate support' [13][14]. Epitalon appears in none of the three categories on either list, and FDA's category 1 policy — under which it generally does not intend to act against compounders who meet the conditions — does not cover it [13][14][15].

In December 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on adding thymosin alpha-1 free base and thymosin alpha-1 acetate to the pharmacy bulks list [16]. On July 24, 2026, the same committee voted in favor of adding epitalon, against FDA staff's recommendation that it not be added; the vote is advice only, and adding a substance takes formal rulemaking [17][18][2]. Epitalon also held an orphan drug designation for retinitis pigmentosa from September 2, 2010; it was withdrawn on January 6, 2016 [2].

HHS's draft enforcement-discretion policy for compounding with certain peptides, filed October 28, 2026, names epitalon among six peptides, covering epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses [18][5]. It does not name thymosin alpha-1 [5]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public,' and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness, or quality before marketing [18].